AMN Stock Analysis: AMN Healthcare | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 1.466m USD | 12M Return: 139.6% | US0017441017 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 37.7M
EPS Trend: -58.7%
Qual. Beats: 3
Rev. Trend: -16.0%
Qual. Beats: 5
Warnings
Tailwinds
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
AMN Healthcare Services, Inc. is a Dallas-based provider of technology-enabled healthcare workforce solutions and staffing services, primarily serving acute and sub-acute care hospitals and other healthcare facilities across the United States. The company operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions, offering a broad range of services including travel nurse staffing, allied health staffing, locum tenens, physician permanent placement, executive search, language services, and vendor management systems. AMN markets its services under multiple brands, including AMN Healthcare, Nursefinders, OGrady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. Founded in 1985 and listed on the NYSE since 2001, the company sits within the Health Care Services sub-industry and is classified as a small-cap stock.
The healthcare staffing industry is highly fragmented, with demand closely tied to clinician shortages, hospital labor cost pressures, and cyclical swings in travel nursing volumes. Workforce optimization and outsourced solutions, such as vendor management systems (VMS), have become an increasingly important part of the value proposition, allowing hospitals to consolidate multiple staffing vendors into a single platform.
- Travel nurse bill rates normalize from pandemic peaks pressuring margins
- Nurse and Allied Solutions revenue declines on softer hospital demand
- International nurse visa policy changes impact permanent placement volumes
| Net Income: 109.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 3.85 > 1.0 |
| NWC/Revenue: 3.92% < 20% (prev 1.04%; Δ 2.89% < -1%) |
| CFO/TA 0.16 > 3% & CFO 360.6m > Net Income 109.0m |
| Net Debt (519.0m) to EBITDA (341.5m): 1.52 < 3 |
| Current Ratio: 1.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.2m) vs 12m ago 3.80% < -2% |
| Gross Margin: 28.40% > 18% (prev 29.37%; Δ -0.97% > 0.5%) |
| Asset Turnover: 158.7% > 50% (prev 127.0%; Δ 31.70% > 0%) |
| Interest Coverage Ratio: 6.08 > 6 (EBIT TTM 202.7m / Interest Expense TTM 33.3m) |
| A: 0.06 (Total Current Assets 803.7m - Total Current Liabilities 665.8m) / Total Assets 2.29b |
| B: 0.58 (Retained Earnings 1.33b / Total Assets 2.29b) |
| C: 0.09 (EBIT TTM 202.7m / Avg Total Assets 2.22b) |
| D: 0.51 (Book Value of Equity 775.0m / Total Liabilities 1.52b) |
| Altman-Z'' = 3.43 = A |
| DSRI: 0.80 (Receivables 460.5m/442.7m, Revenue 3.52b/2.72b) |
| GMI: 1.03 (GM 29.37% / 28.40%) |
| AQI: 0.91 (AQ_t 0.59 / AQ_t-1 0.65) |
| SGI: 1.29 (Revenue 3.52b / 2.72b) |
| TATA: -0.11 (NI 109.0m - CFO 360.6m) / TA 2.29b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of November 19, 2026, the stock is trading at USD 38.10 with a total of 494,159 shares traded. Over the past week, the price has changed by +0.77%, over one month by -5.93%, over three months by +10.31% and over the past year by +139.62%.
Current recommended Stop Loss: 33.60 (which is 11.8% or 1.9 ATR below the current price).
AMN Healthcare has received a consensus analysts rating of 3.44. Therefore, it is recommended to hold AMN.
- StrongBuy: 2
- Buy: 1
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 44.8 | 17.6% |
P/E Trailing = 13.8759
P/E Forward = 18.018
P/S = 0.4169
P/B = 1.8619
P/EG = 1.7113
Revenue TTM = 3.52b USD
EBIT TTM = 202.7m USD
EBITDA TTM = 341.5m USD
Long Term Debt = 743.4m USD (from longTermDebt, last quarter)
Short Term Debt = 6.01m USD (from shortTermDebt, last fiscal year)
Debt = 774.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 31.6m
Net Debt = 519.0m USD (calculated: Debt 774.9m - CCE 256.0m)
Enterprise Value = 1.99b USD (1.47b + Debt 774.9m - CCE 256.0m)
Interest Coverage Ratio = 6.08 (Ebit TTM 202.7m / Interest Expense TTM 33.3m)
EV/FCF = 6.07x (Enterprise Value 1.99b / FCF TTM 327.0m)
FCF Yield = 16.47% (FCF TTM 327.0m / Enterprise Value 1.99b)
FCF Margin = 9.30% (FCF TTM 327.0m / Revenue TTM 3.52b)
Net Margin = 3.10% (Net Income TTM 109.0m / Revenue TTM 3.52b)
Gross Margin = 28.40% ((Revenue TTM 3.52b - Cost of Revenue TTM 2.52b) / Revenue TTM)
Gross Margin QoQ = 31.94% (prev 30.58%)
Tobins Q-Ratio = 0.87 (Enterprise Value 1.99b / Total Assets 2.29b)
Interest Expense / Debt = 4.30% (Interest Expense 33.3m / Debt 774.9m)
Taxrate = 35.64% (60.4m / 169.4m)
NOPAT = 130.5m (EBIT 202.7m * (1 - 35.64%))
Current Ratio = 1.21 (Total Current Assets 803.7m / Total Current Liabilities 665.8m)
Debt / Equity = 1.00 (Debt 774.9m / totalStockholderEquity, last quarter 775.0m)
Debt / EBITDA = 1.52 (Net Debt 519.0m / EBITDA 341.5m)
Debt / FCF = 1.59 (Net Debt 519.0m / FCF TTM 327.0m)
Total Stockholder Equity = 717.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.92% (Net Income 109.0m / Total Assets 2.29b)
RoE = 15.19% (Net Income TTM 109.0m / Total Stockholder Equity 717.8m)
RoCE = 13.87% (EBIT 202.7m / Capital Employed (Equity 717.8m + L.T.Debt 743.4m))
RoIC = 8.95% (NOPAT 130.5m / Invested Capital 1.46b)
WACC = 7.02% (E(1.47b)/V(2.24b) * Re(9.26%) + D(774.9m)/V(2.24b) * Rd(4.30%) * (1-Tc(0.36)))
Discount Rate = 9.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.48 | Cagr: 2.21%
[DCF] Terminal Value 77.97% ; FCFF base≈285.3m ; Y1≈327.1m ; Y5≈481.4m
[DCF] Fair Price = 174.4 (EV 7.24b - Net Debt 519.0m = Equity 6.73b / Shares 38.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -58.74 | EPS CAGR: -28.59% | SUE: 4.0 | # QB: 3
Revenue Correlation: -15.99 | Revenue CAGR: -2.01% | SUE: 1.52 | # QB: 5
EPS current Quarter (2027-03-31): EPS=0.20 | Chg30d=-2.83% | Revisions=-40% | Analysts=7
EPS current Year (2026-12-31): EPS=4.19 | Chg30d=+27.34% | Revisions=+25% | GrowthEPS=+207.9% | GrowthRev=+25.7%
EPS next Year (2027-12-31): EPS=0.94 | Chg30d=+0.18% | Revisions=+29% | GrowthEPS=-77.5% | GrowthRev=-20.8%
[Analyst] Revisions Ratio: +10% (up=4, down=3)